hero-line-left hero-line-top
Product

Improving cancer care through global data sharing

The Syapse Learning Health Network is a global precision oncology data sharing network, improving cancer care across communities by using real-world evidence to support treatment decisions.

hero-line-bottom
hero-line-horizontal
temp-hero-icon

Share comprehensive patient data

The Syapse Learning Health Network enables providers to share and learn from real-world clinical, molecular, treatment, and outcomes data to inform treatment decisions.

Learn from real-world evidence

Oncologists can view which treatments produced the best outcomes in clinically and molecularly similar patients, directly in their clinical workflow.

Join a secure, trusted network

Patient data is standardized and normalized across the network, enabling health systems to securely share de-identified data with other leading institutions.

Imagine treating a patient with metastatic cancer and a rare molecular profile where no standard of care exists. Now, imagine you had a tool that could sift through a large pool of real-world evidence and show you which treatments produced the best outcomes in patients just like them. That’s what Syapse allows us to do.”
Thomas Brown, MD, MBA
Thomas Brown, MDMBA
Executive Director of the Swedish Cancer Institute

Resources

  • Syapse Data Sharing Network brochure (PDF)
  • Syapse Oncology overview brochure (PDF)
  • Implementing an Oncology Precision Medicine Clinic in a Large Community Health System,” by Thompson, et al. in AJMC
  • Building a Personalized Medicine Program,” by Thomas D. Brown of the Swedish Cancer Institute
  • How and When to Implement Precision Oncology,” by Lincoln Nadauld and Derrick S. Haslem of Intermountain Health
  • Role of Community-Based Genomics Programs,” by Thomas D. Brown of the Swedish Cancer Institute

In the news

Amgen taps Syapse to infuse real-world data into its cancer clinical trial designs

5/2/19 - Precision medicine company Syapse has launched a collaboration with its one-time Big Pharma benefactor Amgen, with the goal of mining real-world evidence for insights into cancer drug development. Together, Amgen and Syapse will develop observational research analytics aimed at assessing outcomes in areas of unmet need—starting by identifying existing patients within Syapse’s health network that may be eligible for clinical trials, and then bringing those studies to nearby sites.

Read

Blog

Syapse Expands Security Posture with HITRUST Certification

Patient data collected from electronic health records, molecular testing and patient reported outcomes is powering many of the most exciting…

Read